Biomerica signs exclusive distribution agreement in China for its colorectal screening test with total minimum purchase requirement of $17 million over 7 years and an upfront pre-payment of $1 million.
05 juin 2019 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., June 05, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) announced it has signed an exclusive sales and distribution agreement with MaxHealth for the sale of its EZ Detect...
Biomerica Announces Third Quarter Financial Results
16 avr. 2019 09h18 HE
|
Biomerica, Inc.
IRVINE, Calif., April 16, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) today reported net sales of $4,034,822 for the nine months ending February 28, 2019, compared to $4,433,785 for the...
Biomerica Announces Notice of Allowance for New U.S. Patent Application Covering Diagnostic Guided Therapy for Irritable Bowel Syndrome (IBS)
08 avr. 2019 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for...
Biomerica Announces Updates for H. Pylori Clinical Studies
05 févr. 2019 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today regulatory and clinical advancements in its development program for its H. pylori diagnostic product. ...
Biomerica Announces Second Quarter Financial Results
15 janv. 2019 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., Jan. 15, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) today reported net sales of $1,500,791 for the three months ended November 30, 2018, compared to $1,613,636 for the...
Medline and Biomerica sign agreement for distribution of Biomerica’s colorectal screening test to help identify an early warning sign of colorectal cancer
28 nov. 2018 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., Nov. 28, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) announced that is has signed a three year agreement with Medline Industries for the distribution of Biomerica’s EZ...
Biomerica’s Diagnostic Product Guides Exclusionary Diet Treatment to Successfully Alleviate Symptoms of Ulcerative Colitis (UC) in Prospective Clinical Stud
07 nov. 2018 09h42 HE
|
Biomerica, Inc.
Eliminating positive foods identified by Biomerica’s diagnostic product showed statistically significant improvements (p<0.05) in both Quality of Life (FDA Instrument) and disease activity (Mayo...
Biomerica Reports 1st Quarter Fiscal 2019 Financials
16 oct. 2018 08h30 HE
|
Biomerica, Inc.
Irvine, Calif., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) today reported net sales of $1,272,870 for the three months ending August 31, 2018, compared to $1,444,483 for the...
Biomerica Announces Fiscal Year End 2018 Financial Results
30 août 2018 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported net sales for the fiscal year 2018 were $5,564,185...
Biomerica Receives Notice of Allowance for Irritable Bowel Syndrome (IBS) Test Panel and Methods in Korea
02 août 2018 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) announced today that the Korean Intellectual Property Office (KIPO) has issued a Notice of Allowance for a patent...